Literature DB >> 12852825

Multiple signalling options for prostacyclin.

Helen Wise1.   

Abstract

The fate of a cell following stimulation by the prostanoid prostacyclin is cell specific, depending not only on the ability of prostacyclin to activate the cell surface prostacyclin (IP) receptor and regulate its coupling to various G proteins, but also on its ability to act intracellularly via the nuclear peroxisome proliferator-activated receptor family (PPAR). This review will highlight the different signalling options available to prostacyclin, and discuss the consequences for cell responses.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12852825

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN： 1671-4083            Impact factor:   6.150


  11 in total

1.  Protein kinases A and C regulate receptor-mediated increases in cAMP in rabbit erythrocytes.

Authors:  Shaquria P Adderley; Meera Sridharan; Elizabeth A Bowles; Alan H Stephenson; Mary L Ellsworth; Randy S Sprague
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

2.  The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.

Authors:  Louise S Harrington; Laura Moreno; Anna Reed; Stephen J Wort; Béatrice Desvergne; Christopher Garland; Lan Zhao; Jane A Mitchell
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.752

3.  Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.

Authors:  Emilia Falcetti; Susan M Hall; Peter G Phillips; Jigisha Patel; Nicholas W Morrell; Sheila G Haworth; Lucie H Clapp
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

4.  Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.

Authors:  Takiko Daikoku; Dingzhi Wang; Susanne Tranguch; Jason D Morrow; Sandra Orsulic; Raymond N DuBois; Sudhansu K Dey
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

5.  Endogenous synthesis of prostacyclin was positively regulated during the maturation phase of cultured adipocytes.

Authors:  Mohammad Sharifur Rahman; Ferdous Khan; Pinky Karim Syeda; Kohji Nishimura; Mitsuo Jisaka; Tsutomu Nagaya; Fumiaki Shono; Kazushige Yokota
Journal:  Cytotechnology       Date:  2013-07-25       Impact factor: 2.058

Review 6.  Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 7.  Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.

Authors:  Batoule H Majed; Raouf A Khalil
Journal:  Pharmacol Rev       Date:  2012-06-07       Impact factor: 25.468

8.  Stimulation of fat storage by prostacyclin and selective agonists of prostanoid IP receptor during the maturation phase of cultured adipocytes.

Authors:  Ferdous Khan; Pinky Karim Syeda; Michael Nii N Nartey; Mohammad Shahidur Rahman; Mohammad Safiqul Islam; Kohji Nishimura; Mitsuo Jisaka; Fumiaki Shono; Kazushige Yokota
Journal:  Cytotechnology       Date:  2016-03-05       Impact factor: 2.058

9.  IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues.

Authors:  Emilia Falcetti; David M Flavell; Bart Staels; Andrew Tinker; Sheila G Haworth; Lucie H Clapp
Journal:  Biochem Biophys Res Commun       Date:  2007-07-05       Impact factor: 3.575

10.  Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.

Authors:  Maurizio Cutolo; Barbara Ruaro; Paola Montagna; Renata Brizzolara; Emanuela Stratta; Amelia Chiara Trombetta; Stefano Scabini; Pier Paolo Tavilla; Aurora Parodi; Claudio Corallo; Nicola Giordano; Sabrina Paolino; Carmen Pizzorni; Alberto Sulli; Vanessa Smith; Stefano Soldano
Journal:  Arthritis Res Ther       Date:  2018-05-02       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.